UMD Cancer Researcher Leads Innovation in Metastasis Detection & Treatment

Baltimore, MD – Dr. Stuart S. Martin, a leading researcher at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), is spearheading advancements in cancer diagnostics and treatment, particularly in the critical area of metastasis. His recent appointment underscores UMGCCC’s commitment to pioneering research and personalized cancer care.

Dr. Martin’s work centers on understanding the mechanisms that allow cancer cells to spread, a process known as metastasis, which is responsible for the vast majority of cancer-related deaths. A key focus of his research is a previously little-understood structure on cancer cells – the microtentacle – and how these contribute to the spread of disease.

“Metastasis is the biggest challenge in cancer treatment,” explained a source familiar with Dr. Martin’s research. “If we can understand how cancer cells spread, and detect it early, we can significantly improve patient outcomes.”

The Microtentacle & the Promise of Early Detection

Dr. Martin’s groundbreaking discovery of microtentacles – thin, dynamic membrane protrusions on cancer cells – has shed new light on the mechanics of metastasis. These structures appear to play a crucial role in facilitating the spread of cancer cells to distant organs. By meticulously studying the formation and function of these microtentacles, Dr. Martin and his team are identifying potential therapeutic targets to disrupt the metastatic process.

To facilitate this research, Dr. Martin’s team developed the TetherChip, a novel microfluidic device designed to capture and analyze circulating tumor cells (CTCs) without damaging these delicate structures. Traditional methods of CTC analysis can often distort or destroy microtentacles, hindering accurate assessment. The TetherChip, however, preserves the integrity of these structures, enabling researchers to gain a more comprehensive understanding of metastatic mechanisms.

“The TetherChip is a game-changer,” said another source familiar with the technology. “It allows us to analyze CTCs in a way that was previously impossible, providing valuable insights into the metastatic process.”

The device boasts a robust shelf life exceeding two years and is currently undergoing the final stages of FDA approval, paving the way for potential clinical application. The promise of a rapid and reliable diagnostic tool that can detect early signs of metastasis is a significant step forward in cancer care.

UMGCCC’s Strategic Shift & Commitment to Research

Dr. Martin’s appointment coincides with a strategic shift at UMGCCC, emphasizing a greater focus on interdisciplinary research and translational medicine. The center, designated as a Comprehensive Cancer Center by the National Cancer Institute, is committed to translating scientific discoveries into improved patient care. The center’s comprehensive designation, renewed in 2021, accompanies a $13 million support grant from the NCI, further solidifying its position as a leading cancer research institution.

The merger of the Pharmacology and Physiology departments, spearheaded in part by Dr. Martin, reflects this commitment to collaboration. By fostering a more integrated research environment, UMGCCC aims to accelerate the pace of discovery and innovation. “Bringing together researchers from different disciplines is crucial for tackling complex challenges like cancer,” a UMGCCC spokesperson stated.

Funding & Future Directions

Dr. Martin’s research has attracted over $20 million in funding from prominent sources, including the National Cancer Institute, the Department of Defense, and various cancer foundations. A notable achievement is the five-year, $3.5 million Era of Hope Scholar Award he received from the Department of Defense in 2010, recognizing his innovative work on breast cancer metastasis.

Looking ahead, Dr. Martin’s team plans to leverage the TetherChip technology to develop personalized cancer treatment strategies. By analyzing CTCs from individual patients, researchers hope to identify specific molecular targets and tailor treatment plans accordingly.

“The ultimate goal is to move beyond a one-size-fits-all approach to cancer treatment,” explained a source familiar with Dr. Martin’s vision. “By understanding the unique characteristics of each patient’s cancer, we can develop more effective and targeted therapies.”

UMGCCC’s commitment to innovation, coupled with Dr. Martin’s pioneering research, positions the center at the forefront of cancer care. With continued investment and collaboration, the center is poised to make significant strides in the fight against cancer and improve the lives of patients worldwide.

About UMGCCC: The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is a National Cancer Institute-designated Comprehensive Cancer Center. It brings together multidisciplinary teams of experts to provide comprehensive cancer care, conduct innovative research, and educate future generations of cancer specialists.